Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Endocrinology and Metabolism|October 6, 2005
Effect of cyclic adenosine 3',5'-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomasG Mantovani, S Bondioni, S Ferrero, et al.
Endocrine|February 16, 2016
EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasmsE Sanpaolo, M Miroballo, S Corbetta, et al.
European Journal of Endocrinology|April 9, 2009
Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatmentsC L Ronchi, C Giavoli, E Ferrante, et al.
Molecular Biosystems|January 25, 2013
Urinary exosomes and diabetic nephropathy: a proteomic approachF Raimondo, S Corbetta, L Morosi, et al.
Endocrine-Related Cancer|December 18, 2014
Tumour-associated fibroblasts contribute to neoangiogenesis in human parathyroid neoplasiaC Verdelli, L Avagliano, P Creo, et al.
The Journal of Clinical Endocrinology and Metabolism|April 29, 2011
Increased risk for non-autoimmune hypothyroidism in young patients with congenital heart defectsE Passeri, M Frigerio, T De Filippis, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|November 29, 2011
Epicardial fat thickness significantly decreases after short-term growth hormone (GH) replacement therapy in adults with GH deficiencyE Ferrante, A E Malavazos, C Giavoli, et al.
European Journal of Endocrinology|November 13, 2013
Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patientsM Filopanti, A M Barbieri, G Mantovani, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2011
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter studyM Filopanti, L Olgiati, G Mantovani, et al.
Pageof 7